BioSpecifics Technologies (BioSpecifics Technologies) Debt-to-Equity : 0.00 (As of Sep. 2020)

View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Debt-to-Equity?

BioSpecifics Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $0.08 Mil. BioSpecifics Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $0.11 Mil. BioSpecifics Technologies's Total Stockholders Equity for the quarter that ended in Sep. 2020 was $135.32 Mil. BioSpecifics Technologies's debt to equity for the quarter that ended in Sep. 2020 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioSpecifics Technologies's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of BioSpecifics Technologies was 0.75. The lowest was -0.91. And the median was 0.00.

BSTC's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

BioSpecifics Technologies Debt-to-Equity Historical Data

The historical data trend for BioSpecifics Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies Debt-to-Equity Chart

BioSpecifics Technologies Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Debt-to-Equity

Get a 7-Day Free Trial

BioSpecifics Technologies Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioSpecifics Technologies's Debt-to-Equity

For the Biotechnology subindustry, BioSpecifics Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioSpecifics Technologies's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's Debt-to-Equity falls into.

BioSpecifics Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioSpecifics Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.069	+	0.167)	/	124.491
	=	0.00

BioSpecifics Technologies's Debt to Equity Ratio for the quarter that ended in Sep. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.08	+	0.107)	/	135.315
	=	0.00

BioSpecifics Technologies (NAS:BSTC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioSpecifics Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Wilbur Street, Lynbrook, NY, USA, 11563

Website

https://www.biospecifics.com

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Executives

Paul Gitman	director	167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth	director	191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman	director, 10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman	director	43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N.	director	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison	officer: Chief Financial Officer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi	director, officer: Chief Executive Officer	41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell	officer: Principal Financial Officer	C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law	officer: SVP Business Development	23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman	director, 10 percent owner, officer: President	1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman	10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487